Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H15N.ClH |
Molecular Weight | 185.694 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(N)CC1=CC=CC=C1
InChI
InChIKey=NCAIGTHBQTXTLR-UHFFFAOYSA-N
InChI=1S/C10H15N.ClH/c1-10(2,11)8-9-6-4-3-5-7-9;/h3-7H,8,11H2,1-2H3;1H
Molecular Formula | C10H15N |
Molecular Weight | 149.2328 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00191Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html
Sources: http://www.drugbank.ca/drugs/DB00191
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html
Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 Sources: http://www.drugbank.ca/drugs/DB00191 |
0.31 µM [EC50] | ||
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11911838 |
498.0 µM [Ki] | ||
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11911838 |
375.0 µM [Ki] | ||
Target ID: CHEMBL222 Sources: http://www.drugbank.ca/drugs/DB00191 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ADIPEX-P Approved UseADIPEX-P® is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors Launch Date-3.47241611E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
44.78 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
49.1 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2057.33 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2000 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.63 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
20 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82.5% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Other AEs: Abdominal pain, Dizziness... Other AEs: Abdominal pain (6%) Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12Dizziness (6%) Early satiety (6%) Intermittent headache (6%) Nausea (6%) Swollen lips (6%) Upper respiratory infection (6%) |
37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Other AEs: Anorexia, Back pain... Other AEs: Anorexia (6%) Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12Back pain (6%) Chapped lips (6%) Dry skin (6%) Dyspepsia (6%) Early satiety (6%) Irregular pulse (6%) Nausea (6%) |
390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
Other AEs: Tachycardia, Hypertension... Other AEs: Tachycardia Sources: Hypertension Visual disorders NEC Nausea Insomnia Anxiety |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Disc. AE: Amnesia, Judgement impaired... Other AEs: Disorder sleep, Depression... AEs leading to discontinuation/dose reduction: Amnesia (0.3%) Other AEs:Judgement impaired (0.3%) Memory impairment (0.3%) Paraesthesia (0.3%) Depression (1%) Anxiety (0.3%) Vision blurred (0.3%) Eye pain (0.3%) Abdominal pain (0.3%) Tuberculosis skin test positive (0.3%) Nephrolithiasis (0.3%) Disorder sleep (12.9%) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105Depression (8.1%) Anxiety (9.5%) Cardiac arrhythmia (4.1%) Ischemic heart disease (1%) Disturbance in attention (3.1%) Memory impairment (2%) Cognitive disorders (1.4%) Language disorder (0.3%) Ocular disorders NEC (4.1%) Dyskinesias and movement disorders NEC (1.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Dizziness | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Early satiety | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Intermittent headache | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Nausea | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Swollen lips | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Upper respiratory infection | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Anorexia | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Back pain | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Chapped lips | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Dry skin | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Dyspepsia | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Early satiety | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Irregular pulse | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Nausea | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Anxiety | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Hypertension | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Insomnia | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Nausea | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Tachycardia | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Visual disorders NEC | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Language disorder | 0.3% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Abdominal pain | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Amnesia | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Anxiety | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Eye pain | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Judgement impaired | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Memory impairment | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Nephrolithiasis | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Paraesthesia | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Tuberculosis skin test positive | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Vision blurred | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Ischemic heart disease | 1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Depression | 1% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Cognitive disorders | 1.4% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Dyskinesias and movement disorders NEC | 1.4% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Disorder sleep | 12.9% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Memory impairment | 2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Disturbance in attention | 3.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Cardiac arrhythmia | 4.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Ocular disorders NEC | 4.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Depression | 8.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Anxiety | 9.5% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=17 Page: 17.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39,38 |
major | weak (co-administration study) Comment: In the presence of topiramate, phentermine Cmax and AUC0-inf increased 13 and 42%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39,38 |
PubMed
Title | Date | PubMed |
---|---|---|
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. | 1999 Jul |
|
Peripheral vasculopathy and nephropathy in association with phentermine. | 1999 Jul |
|
Pharmaceutical cost savings of treating obesity with weight loss medications. | 1999 Nov |
|
Histologic changes in three explanted native cardiac valves following use of fenfluramines. | 1999 Sep-Oct |
|
Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. | 2000 Jul 1 |
|
Silver lining to the cloud over anorexogen-related cardiac valvulopathy? | 2001 Feb 20 |
|
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. | 2001 Jan |
|
Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. | 2001 Jul |
|
Pharmacologic options for the treatment of obesity. | 2001 Jul 15 |
|
Bitter pills, bad medicine. | 2001 Jun 4 |
|
Fluorometric determination of DL-fenfluramine, DL-norfenfluramine and phentermine in plasma by achiral and chiral high-performance liquid chromatography. | 2001 Nov 5 |
|
Fenfluramine and phentermine. | 2001 Nov 6 |
|
Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. | 2001 Nov-Dec |
|
Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. | 2001 Oct |
|
Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine. | 2001 Oct |
|
High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label. | 2001 Oct |
|
Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. | 2001 Oct 24-31 |
|
Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol. | 2001 Sep |
|
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. | 2002 |
|
Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. | 2002 Feb |
|
Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. | 2002 Mar-Apr |
|
Appetite suppressants and valvular heart disease. | 2002 Sep |
|
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? | 2002 Sep-Oct |
|
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat. | 2003 Apr |
|
Noradrenergic modulation of ephedrine-induced hypophagia. | 2003 Apr |
|
Ischemic colitis after weight-loss medication. | 2003 Dec |
|
Treatment of obesity: an update on anti-obesity medications. | 2003 Feb |
|
Medical monitoring for pharmaceutical injuries: tort law for the public's health? | 2003 Feb 19 |
|
Obesity: an overview on its current perspectives and treatment options. | 2004 Apr 14 |
|
Going before disciplinary board without counsel is unwise. Case on point: Slone-Vasquez v. Kentucky Board Of Nursing, 2003 WL 22976179 S.W.3d-KY. | 2004 Jan |
|
Pharmacological and surgical treatment of obesity. | 2004 Jul |
|
Taking things to heart. | 2004 Jul |
|
The long-term management of obesity with continuing pharmacotherapy. | 2004 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/phentermine.html
Usual Adult Dose for Weight Loss
15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Usual Pediatric Dose for Weight Loss
17 years or older:
15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10799660
Phentermine inhibited serotonin-metabolizing (MAO-A) activity in rat lung, brain, and liver with K(i) values of 85-88 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:38:30 UTC 2023
by
admin
on
Wed Jul 05 22:38:30 UTC 2023
|
Record UNII |
0K2I505OTV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29728
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
||
|
DEA NO. |
1640
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1574
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
DBSALT000138
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
100000092350
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
M8644
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | Merck Index | ||
|
0K2I505OTV
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
0K2I505OTV
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
DTXSID20152550
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
82078
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | RxNorm | ||
|
C29361
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
1528501
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
70969
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
44090
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
50506
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
214-821-9
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
1197-21-3
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY | |||
|
SUB03767MIG
Created by
admin on Wed Jul 05 22:38:30 UTC 2023 , Edited by admin on Wed Jul 05 22:38:30 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |